Public Meeting on Fibromyalgia Patient-Focused Drug
On December 10, 2013, the U.S. Food and Drug Administration (FDA) is conducting a public meeting on Patient-Focused Drug Development for fibromyalgia. The FDA is interested in obtaining patient input on the impact of fibromyalgia on daily life and patients’ views on currently available therapies to treat the condition.
Date: December 10, 2013
Time: 1:00 p.m. to 5:00 p.m.
Location: FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A (Great Room)
Silver Spring, MD 20993
For information on parking/security at this meeting, please refer to: http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/
To register for this meeting, fibromyalgia patients should visit:
Details on the Meeting
• Federal Register Notice (9/23/2013)
Fibromyalgia Public Meeting on Patient-Focused Drug Development https://www.federalregister.gov/articles/2013/09/23/2013-
• Webinar: Background on FDA and Patient-Focused Drug
Even if you are unable to attend this meeting in person, you can make a very important contribution by responding to a group of questions which have been developed specifically for fibromyalgia patients by the FDA. (Those planning to attend the meeting are also encouraged to submit their answers to these questions.) The questions pertain to two main topics:
• Topic 1: Disease Symptoms and Daily Impacts That Matter
Most to Patients (4 questions)
• Topic 2: Patients’ Perspectives on Current Approaches to
Treating Fibromyalgia (4 questions)
You can access the questions by clicking on the link to the Federal Register Notice included above. Instructions on how and where to submit your responses are also provided there.
Please also share this FDA meeting notice with any other patients in the U.S. who might be interested.
The Food and Drug Administration is part of the U.S. Department of Health and Human Services